Results 61 to 70 of about 5,394 (238)

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

open access: yesMolecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués   +3 more
wiley   +1 more source

Exploration of tumor growth regression of quinoa and chia oil nanocapsules via the control of PIK3CA and MYC expression, anti-inflammation and cell proliferation inhibition, and their hepatorenal safety in rat breast cancer model

open access: yesBulletin of the National Research Centre
Background The second most common cancer in the world is breast cancer. Chemotherapy is used to treat breast cancer, but instances of multidrug resistance, targets that are not selective, and physicochemical issues raise doubts about its efficacy.
Aida I. El makawy   +7 more
doaj   +1 more source

Chronic lymphocytic leukaemia: contemporary conceptions of etiology, pathogenesis and peculiarities of clinical manifestations (review) [PDF]

open access: yesСаратовский научно-медицинский журнал, 2011
The research work presents an analysis of literature review and results of investigations on the problems of etiology, pathogenesis, classification and peculiarities of clinical manifestations of chronic lymphocytic leukaemia.
Chesnokova N.P.   +2 more
doaj  

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Aneuploidías del cromosoma 17 y deleción del Gen TP53 en neoplasias hematológicas

open access: yesIatreia, 2006
La oncogénesis es considerada un proceo de múltiples etapas, en donde los factores genéticos son esenciales para su origen y desarrollo; se afectan principalmente dos grandes grupos de genes; se afectan principalmente dos grandes grupos de genes: los ...
Carlos Mario Muñetón Peña   +5 more
doaj  

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

open access: gold, 2022
Johanna Stachelscheid   +27 more
openalex   +2 more sources

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

MOLECULAR-GENETIC «PORTRAIT» OF BREAST CANCER

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2017
Understanding genetic mechanisms and detection of biological markers of tumor growth forms an individual molecular phenotype oftransformed cells that characterizes stage of tumor, the ability to metastasize, hormonal sensitivity ...
S. A. Laptiev   +2 more
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Biologia molecular do câncer cervical Molecular biology of cervical cancer

open access: yesRevista Brasileira de Saúde Materno Infantil, 2006
A carcinogênese é um processo de múltiplas etapas. Alterações no equilíbrio citogenético ocorrem na transformação do epitélio normal a câncer cervical. Numerosos estudos apoiam a hipótese de que a infecção por HPV está associada com o desenvolvimento de ...
Waldemar Augusto Rivoire   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy